End-stage chronic kidney disease (CKD) is associated with a high prevalence of cardiovascular complications. 1 These CKD patients suffer from a chronic inflammatory process, which causes endothelial injury, 2 a critical event in the pathogenesis of atherosclerosis. 3, 4 Furthermore, in these patients, uremic toxins and inflammation are more potent predictors of arteriosclerosis than the classic risk factors such as hypertension, dyslipoproteinemia, obesity, and smoking; 5, 6 markers of inflammation such as C-reactive protein and cytokines are independent predictors of all cause and cardiovascular mortality. [7] [8] [9] In the last years, research in the biology of the endothelium has provided new targets to examine endothelial damage and repair in human pathology. Upon a noxious insult, endothelial cells may undergo vesiculation ensuing in the release of microparticles 'endothelial microparticles' (EMP) into the bloodstream. EMP express endothelialspecific surface markers reflective of parent cell status (e.g., activated and apoptotic). 10 On the other hand, the mobilization of bone marrow-derived endothelial progenitor cells (EPC) is critical for the preservation of the integrity of endothelium. 11 Endothelial repair requires the presence of EPC, which originate from the bone marrow as demonstrated by the expression of CD34 (a surface marker common to hematopoietic stem cells and mature endothelial cells) and vascular endothelial cell growth-factor receptor 2 (VEGFR2 or kinase domain-related (KDR) receptor). 12 Several studies have shown evidence of endothelial damage and dysfunction in hemodialysis patients. Increased levels of apoptotic EMP have been reported in plasma from CKD-5 patients. In addition, several authors have reported that in CKD-4-5 patients there is a decrease in EPC; 13 however, these findings are not uniform as other groups have reported a normal 14 or even increased number of circulating EPC. 15 The potential for reversal of vascular disease in CKD-5 patients is unknown. The quality and technology of hemodialysis have improved in relation to biocompatibility of the materials used and the ability to remove larger size uremic toxins molecules. By combining ultrafiltration (convective clearances for removing larger solutes) with diffusion (for removal of small solutes), on-line hemodialfiltration (OL-HDF) offers a highly effective dialysis modality expanding the spectrum of removed uremic toxins from small to middle-sized molecular solutes. Recently, OL-HDF has been associated with a significant reduction of inflammation and improved survival. 16, 17 The aim of this study was to examine whether amelioration of microinflammation using OL-HDF has an effect on EMP and ECP as biomarkers of endothelial injury and repair, respectively. Table 1 illustrates the characteristics and laboratory data of patients included in the study at baseline. These parameters remained unchanged during the study.
RESULTS Patients

Evaluation of CD14 and CD16 mononuclear expression
As compared with normal subjects, at baseline (after 2 months on high-flux hemodialysis (HF-HD)), CKD-5 patients exhibited a high percentage of peripheral blood mononuclear cells (PBMC) positive for CD14 and CD16 as compared with healthy controls (20.372.3% vs 4.572.5%; P ¼ 0.001). After 4 months on OL-HDF, these same patients showed a marked decrease in the percent of CD14 þ CD16 þ cells (14.973.2%, P ¼ 0.001). A decrease in CD14 þ CD16 þ cells after OL-HDF was observed in all 15 patients. During the following period, (back to HF-HD), the percent of CD14 þ CD16 þ cells increased to 19.272.8% (Po0.001 vs OL-HDF) ( Table 2) .
Evaluation of CD31 þ /Annexin V þ EMP and EPC
As observed in a representative histogram from the flowcytometer (Figure 1 ), samples from HF-HD patients at baseline showed an increased number of EPC annexin-V þ / CD31 þ as compared with healthy subjects. In addition, in PBMC from HF-HD patients at baseline the percentage of CD31, CD14, and VEGFR2 EPC is increased as compared with controls ( Figure 2 ).
Patients on HF-HD (baseline) presented a high number of EMP events (21.377.4 events/ml vs controls, P ¼ 0.001, Figure 3a ). After 4 months on OL-HDF, the number of events significantly decreased in all but one patient (15.475.5 events/ml, P ¼ 0.045 vs baseline). During the following 4 months of HF-HD, the number of events increased in all patients to 20.976.0 events/ml, a level superimposable to that of baseline. Figure 3b shows a high percentage of EPC in HF-HD patients at baseline in comparison with controls (30.877.1%, P ¼ 0.001). After 4 months on OL-HDF, the number of events significantly decreased to 20.875.4% (P ¼ 0.001 vs baseline). In the following 4 months of HF-HD, the number of EPC returned to a level superimposable to that of baseline (29.274.0, P ¼ 0.001 vs OL-HDF, P ¼ 0.9 vs baseline). Interestingly, the number of CD14 þ CD16 þ cells correlated significantly with both EMP (r ¼ 0.63, P ¼ 0.003; Figure 4a ) and EPC (r ¼ 0.57, P ¼ 0.004; Figure 4b ) in blood samples from HF-HD and OL-HDF. However, there was no correlation between EPC and EMP (data not shown).
To evaluate the effects of one dialysis session of each modality on endothelial damage, EPC and EMP were evaluated before and after a treatment session at the beginning of each of the two periods. Although EMP increased significantly at the end of HF-HD (at both, baseline and after the last 4 months on HF-HD), no significant changes occurred after OL-HDF. A significant reduction of EPC was observed in both HF-HD and in OL-HDF ( Figure 5 ). These results could not be attributed to a dilutional effect, as net fluid balance was not different in both procedures.
DISCUSSION
Our results clearly show that a significantly high number of circulating CD31 þ /Annexin V þ EMP were observed in patients on HD-HF as compared with healthy controls. The elevated number of EMP was associated with an also remarkably high count of EPC. Both circulating EMP and EPC were reduced after 4 months of OL-HDF. This study confirms our previously published data on the reduction of proinflammatory CD14 þ CD16 þ monocytederived dendritic cells in patients on OL-HDF. 17 This study shows that the rise of CD14 þ CD16 þ cells is associated with proportional increases in both ECM and EPC.
An emerging interest has been drawn from recent human studies underlying the association of EMP to endothelial dysfunction and arterial dysfunction in CKD. 18, 19 By the linear regression analysis, we documented a significant correlation between proinflammatory CD14 þ CD16 þ cells, and both the number of EMP as well as the number of EPC. It is tempting to speculate that CD14 þ CD16 þ monocytederived dendritic cells may have a dual effect triggering endothelial activation and injury leading to the release of EMP and the stimulation of the bone marrow to increase the production of circulating EPC. We were unable to claim a direct cause-and-effect relationship between microinflammation, formation of EMP, and increased numbers of circulating EPC. Other factors such as uremic toxins, or other activated cells (e.g., platelets, leukocytes) may come into play. Jacobi et al. 20 have implicated the priming of polymorphonuclear neutrophils as the main mechanism of the initiation of endothelial injury.
It is of interest that no increase in EMP was observed in postdialysis blood samples after OL-HDF. In all cases, HF-HD was associated with a remarkable increase of EMP. In both HF-HD and OL-HDF, EPC decreased significantly in the postdialysis blood samples in respect to the predialysis ones. The unique relevance of convection on the observed changes was due to the fact that both dialysis modalities, HD-HF and OL-HDF were in fact equal for the membrane used and water quality. To insure uniform procedures and quality standards, we performed these studies in one single center. Our study shows, for the first time, that reduction of the monocyte subpopulation responsible for cytokine production by OL-HDF may decrease the damage of the endothelium.
Our study has a number of limitations. First, the lack of randomization of the patients to different sequences of treatments might in principle have left the potential for residual confounding by unrecognized factors or cointerventions over time. However, as in our previous publication, also in the present studies we observed that the percent of CD14 þ /CD16 þ cells was not changed after 4 months of HF-HD (first and third period), thus attenuating a major impact by time and/or seasonal factors. Second, although EPM and EPC are considered as markers of endothelial damage and repair, respectively, they cannot be considered as surrogate measures for cardiovascular outcome. Furthermore, there are controversies on the identification, definition, and significance of EPC in the pathophysiology of different diseases. According with Ingram et al., 12 our EPC were sorted by three monoclonal antibodies anti-CD14, -CD31, and -VEGFR2. The latter has been shown to be expressed on peripheral blood cells that proliferate in vivo and that contribute to re-endothelialization. Recent studies also suggest that circulating detached endothelial cells and stimulated EPC from the bone marrow may reflect endothelial injury. 21, 22 In this study, we did not assess the plasma levels of VEGF, a stimulus for EPC release from bone marrow. Therefore, we cannot exclude that VEGF levels may have some responsibility of the observed changes. Also erythropoietin (EPO) is a strong stimulus for EPC release. However, there was no significant change in the routine EPO dose in any of the patients throughout the study period. Third, the effect of OL-HDF was only 15%, whereas the difference between patients and healthy controls was far more substantial (400% higher levels in patients than in healthy subjects). Even the most effective dialysis technique (OL-HDF) was far from producing a biologically relevant effect on endothelial dysfunction. Nevertheless, one must remember that the patient population was selected to identify patients who had no signs or symptoms as well as laboratory markers of an ongoing overt inflammation (as shown by stably low C-reactive protein and EPO dose during the 8-month follow up. In a cross-sectional study, Chan et al. 15 showed the normalization of EPC counts and function in patients on nocturnal daily hemodialysis for at least 1 year.
Finally, the uremic milieu may also play a role. Faure et al. 19 evaluated the effect of specific uremic factors on EMP release in vitro, and showed that some uremic toxins such as p-cresol and indoxyl sulfate are able to induce the vesiculation of cultured endothelial cells. Bammens et al. 23 showed that OL-HDF significantly reduces the levels of p-cresol in respect to HF-HD, thus possibly suggesting an effect of high convective transfer in the removal of a wider spectrum of uremic toxins than that observed in predominantly diffusive therapies such as HF-HD.
The beneficial effect of high convective transport (OL-HDF) may be directly caused by modulation of proinflammatory CD14 þ CD16 þ monocyte-derived dendritic cells or by a more complex interaction that also encompasses removal of a wider spectrum of uremic toxins. Whatever the mechanism/s might be at work, OL-HDF is associated with less formation of EMP and release of EPC in the circulation.
In conclusion, our studies provide the evidence that microinflammation is associated to endothelial damage and that amelioration of the microinflammatory status using high convective transport appears to reduce endothelial damage. Further studies will need to warrant whether long-term OL-HDF attenuates endothelial dysfunction and microinflammation in patients with overt systemic inflammation and whether this can be associated to the improved survival.
MATERIALS AND METHODS Study design
A total of 15 stable HD patients were included. All patients had been treated for more than 6 months in the satellite dialysis facility of Reina Sofia University Hospital of Cordoba and remained in the same facility throughout the study. The same group of patients was sequentially treated with two different modalities of HD during 4 months each: HF-HD and OL-HDF. Both procedures are regularly used in patients on maintenance hemodialysis; however, OL-HDF offers more convective transport, which results in removal of a wider spectrum of uremic toxins. All patients were on HF-HD during at least 2 months (baseline), then, patients were switched to OL-HDF for an additional period of 4 months and finally patients were changed back to HF-HD for 4 months. Five apparently healthy subjects (age: 4976 years; gender: male 3/female 2) were studied.
Patient and baseline data
At baseline all patients were on HF-HD using polysulfone membranes (1.8 m 2 , HF80, Fresenius Medical Care, Bad Homburg, Germany) using 4008 dialysis monitors (Fresenius Medical Care). HF-HD and OL-HDF were performed with ultrapure bicarbonatebuffered dialysate three times a week. The average volume of on-line reinfusion fluid per session was 19.7 l (range: 17.0-24.1). Analysis of the dialysis system always revealed absence of bacteria (o100 cfu/ml (colony-forming units/milliliter)) or bacteriological contaminant products (endotoxin levels below 0.025 endotoxin units) during the whole period of the study. The dialysis characteristics were similar in the two modalities, the only difference being a higher convective transport in the OL-HDF than HF-HD. The therapeutic regime consisted in EPO, calcium-containing phosphate binders, antihypertensive drugs, and intravenous iron. All patients were on EPO from the beginning of the study. EPO dosage was adjusted to maintain the hemoglobin target of 11.5-12 g/dl. Weekly EPO dose was similar in both modalities of HD along the study. Patients with symptoms or signs of inflammation, infection, and cancer were excluded. None of the patients were on anti-inflammatory or immunosuppressive drugs during the 3 months before inclusion and for the whole period of the study. None of them had diabetes. Informed consent was obtained from all patients. All routine laboratory measurements were done using certificate assay methods.
The effect of each experimental period was assessed, by obtaining the blood samples just before the first dialysis session of the following study period. To analyze the effects of one dialysis session of each dialysis modalities (HF-HD and OL-HDF), blood samples were obtained just before and after the corresponding first weekly dialysis session.
Experimental procedures
Human mononuclear cell culture. PBMC and plasma were obtained from 20 ml of citrate-buffered blood drawn immediately before dialysis session. To analyze the effect of a single dialysis procedure, blood samples were obtained before and after completion of the dialysis session. Buffy coat cells were separated by differential centrifugation gradient (Ficoll/Hypaque; Pharmacia LKB, Uppsala, Sweden). Thereafter, cells were washed and seeded in 12-well at 371C in complete culture medium containing RPMI-1640 supplemented with L-glutamine (2 mM), Hepes (20 mM), sodium pyruvate (1 mM), streptomycin (50 ng/ml), penicillin (100 UI/ml), and 10% human autologous serum (Bio-Whittaker, Walkersville, MD, USA). Serum was heated (561C, 60 min) to inactivate complement.
Cytometric bead array immunoassay. The amount of cytokines in plasma was evaluated using a Cytometric bead array immunoassay. The cytometric bead array technique was based on the binding of microparticles labeled with different fluorescence intensities to antibodies. The maximum wavelength emission was about 650 nm (fluorescence-3 channel). The particles were bound by a covalent bond to an antibody against one of the cytokines tumor necrosis factor-a or interleukin-6 (Pharmingen, San Diego, CA, USA). This method allowed the simultaneous determination of different cytokines in the same sample. The cytokines were captured directly in the immunoassay using different antibodies bound to phycoerythrin (PE), which emitted at 585 nm (fluorescence-2 channel). The PE-conjugated detector antibody completed the sandwich, and the intensity measured in fluorescence-2 channel was proportional to the concentration of cytokines in the sample, which was quantified from a calibration curve. An important characteristic of the assay system was that the calibrators, the antibody-bead reagent, and the second antibody reagent, antibody-PE were made from mixtures of cytokines. Standard curves (0-5000 pg/ml) were derived from a set of calibrators and the same set was used for all assays. Then, 50 ml of the sample or cytokine standard was added to the mixture of 50 ml each of antibody-PE detector and antibody-bead reagent. The mixture (150 ml) was incubated for 160 min in the dark at room temperature, washed, and the test samples were acquired using the flow cytometer.
Evaluation of CD14 and CD16 mononuclear expression. To quantify proinflammatory cells (CD14 þ CD16 þ ) a sample of 10 5 /ml PBMC was incubated during 30 min, at 41C with the monoclonal antibodies (Mab) M5E2 against the molecule CD14 and 3G8 against the molecule CD16 (Becton Dickinson, San José, CA, USA). Cytofluorometric analysis was performed with a FACSCalibur cytometer (Becton Dickinson).
Determination. of CD31 þ /Annexin V þ EMP. Apoptotic ECM were isolated as described earlier. 10 Plasma derived from 20-ml citrate-buffered blood was separated from whole blood and immediately centrifuged at 13 000 g for 5 min to generate plateletpoor plasma. Platelet-poor plasma (50 ml) was incubated with 4 ml of monoclonal antibody against CD31 (MHCD3104-PE Caltag Lab, Burlingame, CA, USA) followed by incubation with fluorescein isothiocyanate-conjugated Annexin V kits according to the manufacturer's instructions (Bender MedSystem, Vienna, Austria). Fluorescence-activated cell sorter analysis was performed in a FACSCalibur cytometer. The negative control (zero value) was the value obtained using the isotype antibodies. Each result (one single value) was the average of three independent determinations of the same sample.
Characterization of EPC. The EPCs were defined as cells triplepositive for CD31, CD14, and VEGFR2. 12 Previous studies have demonstrated that these cells are actively involved in endothelial repair. 12. Immediately after blood extraction, PBMC were separated by Ficoll, washed with phosphate-buffered saline, and resuspended in EBM-2 medium supplemented with antibiotics and 20% of fetal bovine serum. Thereafter 2 Â 10 6 cells were incubated for 30 min in the dark at 41C with saturating concentrations of the following monoclonal antibodies (mAb): anti-VEGFR2 (antihuman VEGFR2 KDR-PE; R&D System, Minneapolis, MN USA), anti-CD31 (MHCD3101FITC, Caltag Lab), and anti-CD14 (MHCD1406TRI-COLOR) and corresponding isotype controls. Then, cells were washed with phosphate-buffered saline, and the test samples were analyzed using the flow cytometer. Quantitative analysis was performed on a FACSCalibur cytometer (Becton Dickinson) measuring 200 000 events per sample. Data were analyzed using CELLQuest software (Becton Dickinson) by side scatter-fluorescence dot plot analysis. The number of EPCs was defined as events triplepositive for CD31, CD14, and VEGFR2. The negative control (zero value) was the value obtained using the isotype antibodies. Each result (one single value) was the average of three independent determinations of the same sample.
Statistical analysis. Comparison between means from different periods was performed by repeated measures analysis of variance followed by Bonferroni test. The comparison of two means was done by Student's t-test for paired data. Non-parametric data were analyzed by Wilcoxon or Mann-Whitney test for paired and unpaired comparison, respectively. The Spearman rank correlation coefficient was used to analyze correlation. Differences were considered significant when Po0.05.
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